Sionna Competitors
| SION Stock | 36.53 1.49 3.92% |
Sionna Therapeutics vs Immunome Correlation
Weak diversification
The correlation between Sionna Therapeutics Common and IMNM is 0.39 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Sionna Therapeutics Common and IMNM in the same portfolio, assuming nothing else is changed.
Moving against Sionna Stock
| 0.54 | EVGN | Evogene | PairCorr |
| 0.53 | KRRO | Frequency Therapeutics | PairCorr |
| 0.39 | JUMP | Leveljump Healthcare Corp | PairCorr |
Sionna Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sionna Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Sionna and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sionna Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Sionna Stock performing well and Sionna Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sionna Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| JANX | 3.34 | (0.84) | 0.00 | (0.48) | 0.00 | 7.88 | 63.52 | |||
| ABCL | 3.40 | (0.73) | 0.00 | (0.17) | 0.00 | 6.33 | 28.69 | |||
| MAZE | 2.87 | 0.72 | 0.22 | 1.47 | 2.65 | 6.77 | 20.03 | |||
| BHVN | 4.08 | 0.73 | 0.16 | (2.65) | 3.64 | 10.23 | 29.39 | |||
| CLDX | 2.49 | 0.00 | 0.00 | 0.09 | 2.90 | 6.44 | 14.68 | |||
| VERA | 3.66 | 0.84 | 0.30 | 0.48 | 2.57 | 10.77 | 23.44 | |||
| XERS | 2.60 | (0.44) | 0.00 | (0.62) | 0.00 | 4.71 | 21.88 | |||
| ZYME | 2.88 | 0.46 | 0.11 | (2.61) | 2.86 | 5.40 | 36.09 | |||
| ARDX | 3.03 | 0.32 | 0.10 | 0.41 | 2.85 | 8.50 | 25.22 | |||
| IMNM | 3.51 | 0.73 | 0.18 | 0.65 | 3.86 | 7.87 | 31.45 |
Cross Equities Net Income Analysis
Compare Sionna Therapeutics and related stocks such as Janux Therapeutics, Abcellera Biologics, and Maze Therapeutics Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JANX | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (6.8 M) | (32.6 M) | (54.2 M) | (58.3 M) | (69 M) | (62.1 M) | (59 M) |
| ABCL | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | (2.2 M) | 118.9 M | (2.2 M) | 158.5 M | (146.4 M) | (162.9 M) | (146.6 M) | (139.2 M) |
| MAZE | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (100.4 M) | 52.2 M | 60.1 M | 63.1 M |
| BHVN | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (528.8 M) | (118.7 M) | (213.8 M) | (570.3 M) | (408.2 M) | (846.4 M) | (761.8 M) | (723.7 M) |
| CLDX | (1.7 M) | (44.8 M) | (59.1 M) | (81.5 M) | (118.1 M) | (127.2 M) | (128.5 M) | (93 M) | (151.2 M) | (50.9 M) | (59.8 M) | (70.5 M) | (112.3 M) | (141.4 M) | (157.9 M) | (142.1 M) | (135 M) |
| VERA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (53.4 M) | (32.6 M) | (89.1 M) | (96 M) | (152.1 M) | (136.9 M) | (130.1 M) |
| XERS | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (26.6 M) | (60.1 M) | (125.6 M) | (125.6 M) | (122.7 M) | (94.7 M) | (62.3 M) | (54.8 M) | (49.4 M) | (51.8 M) |
| ZYME | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (19.2 M) | (33.8 M) | (10.4 M) | (36.6 M) | (145.4 M) | (180.6 M) | (211.8 M) | 124.3 M | (118.7 M) | (122.7 M) | (110.4 M) | (115.9 M) |
| ARDX | (9.8 M) | (9.8 M) | (9.8 M) | (6.6 M) | (3.2 M) | (29.6 M) | (112.4 M) | (64.3 M) | (91.3 M) | (94.9 M) | (94.3 M) | (158.2 M) | (67.2 M) | (66.1 M) | (39.1 M) | (35.2 M) | (37 M) |
| IMNM | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (10.6 M) | (17.1 M) | (24.7 M) | (36.9 M) | (106.8 M) | (293 M) | (263.7 M) | (250.5 M) |
Sionna Therapeutics and related stocks such as Janux Therapeutics, Abcellera Biologics, and Maze Therapeutics Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Sionna Therapeutics financial statement analysis. It represents the amount of money remaining after all of Sionna Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Sionna Therapeutics Competitive Analysis
The better you understand Sionna Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sionna Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sionna Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Sionna Therapeutics Competition Performance Charts
Five steps to successful analysis of Sionna Therapeutics Competition
Sionna Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sionna Therapeutics in relation to its competition. Sionna Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Sionna Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sionna Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sionna Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Sionna Therapeutics position
In addition to having Sionna Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Value Funds Thematic Idea Now
Large Value Funds
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Value Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sionna Therapeutics Correlation with its peers. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could Sionna diversify its offerings? Factors like these will boost the valuation of Sionna Therapeutics. If investors know Sionna will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sionna Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Sionna Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sionna Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Sionna Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Sionna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sionna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sionna Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.